title: Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
authors.forename: B W
authors.initials: BW
authors.lastname: Teh
authors.forename: L J
authors.initials: LJ
authors.lastname: Worth
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077716:Afatinib; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D003556:Cystitis / Q000209:etiology / Q000821:virology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D004941:Esophagitis / Q000209:etiology / Q000821:virology; D006417:Hematuria / Q000209:etiology / Q000821:virology; D006561:Herpes Simplex / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007416:Intestinal Perforation / Q000209:etiology / Q000821:virology; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D010538:Peritonitis / Q000209:etiology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014766:Viremia / Q000209:etiology / Q000821:virology; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir